Nitidine chloride may mediate its antitumor effects by targeting kinesin family member 20A in colorectal cancer cells.

IF 3.2 Q3 ONCOLOGY
Ke-Jun Wu, Da-Tong Zeng, Rong-Quan He, Dong-Ming Li, Jin-Lian Yao, Li-Min Liu, Wei-Jian Huang, Di-Yuan Qin, Yu-Feng Li, Han He, Shi-De Li, Jia-Ying Wen, Li Meng, Jia-Rong Shi, Gang Chen, Hui Li
{"title":"Nitidine chloride may mediate its antitumor effects by targeting kinesin family member 20A in colorectal cancer cells.","authors":"Ke-Jun Wu, Da-Tong Zeng, Rong-Quan He, Dong-Ming Li, Jin-Lian Yao, Li-Min Liu, Wei-Jian Huang, Di-Yuan Qin, Yu-Feng Li, Han He, Shi-De Li, Jia-Ying Wen, Li Meng, Jia-Rong Shi, Gang Chen, Hui Li","doi":"10.5306/wjco.v16.i7.108666","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prevalence of colorectal cancer (CRC) in younger people is increasing. Despite advances in precision medicine, the challenges of drug resistance and high costs persist. Nitidine chloride (NC) has pharmacological potential, and kinesin family member 20A (KIF20A) is overexpressed in various tumors; however, their interaction in CRC remains unexplored.</p><p><strong>Aim: </strong>To investigate the KIF20A expression characteristics in CRC cells and determine whether it is a potential target gene for NC in inhibiting CRC treatment.</p><p><strong>Methods: </strong>Single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and mRNA expression profiling were used to analyze KIF20A expression in CRC cells. Immunohistochemical staining was used to verify KIF20A expression in 416 clinical samples (208 CRC tissue samples and 208 noncancerous control tissue samples). Clustered regularly interspaced short palindromic repeats (CRISPR) technology was used to evaluate the impact of knocking out KIF20A on CRC cell growth. Molecular docking was applied to analyze NC-KIF20A binding. Finally, RNA sequencing and functional enrichment analysis were performed to explore the mechanism of action of NC in CRC cells.</p><p><strong>Results: </strong>Treating HCT116 cells with NC was found to significantly downregulate KIF20A (<i>P</i> < 0.05), and the molecular docking analysis revealed high-affinity binding between NC and KIF20A (binding energy = -9.6 kcal/mol). The scRNA-seq, spatial transcriptomics, and mRNA expression profiling results confirmed the significantly high expression of KIF20A in CRC tissues (standardized mean difference = 1.33, 95% confidence interval: 0.885-1.77, summary receiver operating characteristic curve area = 0.94). The immunohistochemical analysis of the clinical samples showed high KIF20A expression in the CRC tissues (<i>P</i> < 0.05), with significant correlation between the level of expression and gender, tumor size, and tumor grade (<i>P</i> < 0.05). Knocking out KIF20A significantly inhibited the growth of various CRC cell lines (CRISPR score < -0.3). The functional enrichment analysis indicated that NC may inhibit CRC by disrupting several biological processes, such as mitotic nuclear division, chromosome segregation, and microtubule binding.</p><p><strong>Conclusion: </strong>Our results indicate that NC binds to KIF20A with high affinity and downregulates its expression in CRC cells, leading to reduced proliferation. Hence, NC has promise as a therapeutic agent in the treatment of CRC, and targeting KIF20A also has potential as a therapeutic strategy. Further KIF20A knockout studies are needed to confirm the binding specificity and mechanistic roles of NC in CRC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108666"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305096/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i7.108666","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The prevalence of colorectal cancer (CRC) in younger people is increasing. Despite advances in precision medicine, the challenges of drug resistance and high costs persist. Nitidine chloride (NC) has pharmacological potential, and kinesin family member 20A (KIF20A) is overexpressed in various tumors; however, their interaction in CRC remains unexplored.

Aim: To investigate the KIF20A expression characteristics in CRC cells and determine whether it is a potential target gene for NC in inhibiting CRC treatment.

Methods: Single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and mRNA expression profiling were used to analyze KIF20A expression in CRC cells. Immunohistochemical staining was used to verify KIF20A expression in 416 clinical samples (208 CRC tissue samples and 208 noncancerous control tissue samples). Clustered regularly interspaced short palindromic repeats (CRISPR) technology was used to evaluate the impact of knocking out KIF20A on CRC cell growth. Molecular docking was applied to analyze NC-KIF20A binding. Finally, RNA sequencing and functional enrichment analysis were performed to explore the mechanism of action of NC in CRC cells.

Results: Treating HCT116 cells with NC was found to significantly downregulate KIF20A (P < 0.05), and the molecular docking analysis revealed high-affinity binding between NC and KIF20A (binding energy = -9.6 kcal/mol). The scRNA-seq, spatial transcriptomics, and mRNA expression profiling results confirmed the significantly high expression of KIF20A in CRC tissues (standardized mean difference = 1.33, 95% confidence interval: 0.885-1.77, summary receiver operating characteristic curve area = 0.94). The immunohistochemical analysis of the clinical samples showed high KIF20A expression in the CRC tissues (P < 0.05), with significant correlation between the level of expression and gender, tumor size, and tumor grade (P < 0.05). Knocking out KIF20A significantly inhibited the growth of various CRC cell lines (CRISPR score < -0.3). The functional enrichment analysis indicated that NC may inhibit CRC by disrupting several biological processes, such as mitotic nuclear division, chromosome segregation, and microtubule binding.

Conclusion: Our results indicate that NC binds to KIF20A with high affinity and downregulates its expression in CRC cells, leading to reduced proliferation. Hence, NC has promise as a therapeutic agent in the treatment of CRC, and targeting KIF20A also has potential as a therapeutic strategy. Further KIF20A knockout studies are needed to confirm the binding specificity and mechanistic roles of NC in CRC.

氯化尼替丁可能通过靶向结直肠癌细胞中激酶家族成员20A介导其抗肿瘤作用。
背景:结直肠癌(CRC)在年轻人中的患病率正在上升。尽管精准医疗取得了进步,但耐药性和高成本的挑战依然存在。Nitidine chloride (NC)具有药理潜力,激酶家族成员20A (KIF20A)在多种肿瘤中过表达;然而,它们在CRC中的相互作用仍未被探索。目的:探讨KIF20A在结直肠癌细胞中的表达特征,确定其是否为NC抑制结直肠癌治疗的潜在靶基因。方法:采用单细胞RNA测序(scRNA-seq)、空间转录组学和mRNA表达谱分析KIF20A在结直肠癌细胞中的表达。采用免疫组织化学染色法验证了416例临床样本(208例结直肠癌组织样本和208例非癌对照组织样本)中KIF20A的表达。聚类规则间隔短回文重复序列(CRISPR)技术用于评估敲除KIF20A对CRC细胞生长的影响。采用分子对接方法分析NC-KIF20A的结合。最后通过RNA测序和功能富集分析,探讨NC在结直肠癌细胞中的作用机制。结果:NC处理HCT116细胞可显著下调KIF20A (P < 0.05),分子对接分析显示NC与KIF20A具有高亲和力结合(结合能= -9.6 kcal/mol)。scRNA-seq、空间转录组学和mRNA表达谱结果证实了KIF20A在结直肠癌组织中的显著高表达(标准化平均差异= 1.33,95%置信区间:0.885-1.77,总接受者工作特征曲线面积= 0.94)。临床样本免疫组化分析显示,KIF20A在结直肠癌组织中高表达(P < 0.05),表达水平与性别、肿瘤大小、肿瘤分级有显著相关性(P < 0.05)。敲除KIF20A显著抑制各种CRC细胞系的生长(CRISPR评分< -0.3)。功能富集分析表明,NC可能通过破坏有丝分裂核分裂、染色体分离和微管结合等生物过程来抑制CRC。结论:我们的研究结果表明,NC与KIF20A高亲和力结合,并下调其在结直肠癌细胞中的表达,导致增殖减少。因此,NC有望成为一种治疗结直肠癌的药物,而靶向KIF20A也有可能成为一种治疗策略。需要进一步的KIF20A敲除研究来确认NC在CRC中的结合特异性和机制作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
585
期刊介绍: The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信